Valbiotis (EPA:ALVAL) Full Year 2023 Results
Key Financial Results
- Revenue: €6.81m (up by €6.02m from FY 2022).
- Net loss: €7.37m (loss narrowed by 40% from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Valbiotis Earnings Insights
Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Biotechs industry in France.
Performance of the French Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for Valbiotis that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALVAL
Valbiotis
Engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France.
Flawless balance sheet moderate.
